S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NYSE:TEVA

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

$13.13
+0.04 (+0.31%)
(As of 02/29/2024 ET)
Today's Range
$13.01
$13.21
50-Day Range
$10.44
$13.31
52-Week Range
$7.09
$13.53
Volume
10.52 million shs
Average Volume
10.35 million shs
Market Capitalization
$14.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.75

Teva Pharmaceutical Industries MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
4.7% Upside
$13.75 Price Target
Short Interest
Healthy
1.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$3.63 M Sold Last Quarter
Proj. Earnings Growth
10.48%
From $2.29 to $2.53 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

532nd out of 958 stocks

Pharmaceutical Preparations Industry

239th out of 430 stocks


TEVA stock logo

About Teva Pharmaceutical Industries Stock (NYSE:TEVA)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

TEVA Stock Price History

TEVA Stock News Headlines

6 reasons to buy Teva Pharmaceuticals stock sooner than later
Teva Pharmaceutical Industries Ltd. NYSE: TEVA is a global pharmaceutical company in the medical sector specializing in generic and specialty medications.
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
TEVA Sep 2024 18.000 put
TEVA Jun 2024 11.000 put
TEVA Apr 2024 13.000 put
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
TEVA Stock Pops 4% as Teva Receives FDA Approval
TEVA Mar 2024 14.000 put
TEVA Sep 2024 8.000 call
TEVA Feb 2024 12.000 call
Teva Pharmaceutical upgraded at Piper Sandler
Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
2/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
37,851
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.75
High Stock Price Target
$19.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+4.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-559,000,000.00
Pretax Margin
-3.94%

Debt

Sales & Book Value

Annual Sales
$15.85 billion
Cash Flow
$3.47 per share
Book Value
$7.25 per share

Miscellaneous

Outstanding Shares
1,121,090,000
Free Float
1,114,143,000
Market Cap
$14.72 billion
Optionable
Optionable
Beta
1.01
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report














TEVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TEVA shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price target for 2024?

9 equities research analysts have issued 1 year target prices for Teva Pharmaceutical Industries' stock. Their TEVA share price targets range from $10.00 to $19.00. On average, they expect the company's stock price to reach $13.75 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2024?

Teva Pharmaceutical Industries' stock was trading at $10.44 at the beginning of the year. Since then, TEVA stock has increased by 25.8% and is now trading at $13.13.
View the best growth stocks for 2024 here
.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a drop in short interest during the month of February. As of February 15th, there was short interest totaling 15,390,000 shares, a drop of 16.0% from the January 31st total of 18,320,000 shares. Based on an average trading volume of 10,460,000 shares, the short-interest ratio is presently 1.5 days.
View Teva Pharmaceutical Industries' Short Interest
.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TEVA earnings forecast
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its earnings results on Wednesday, January, 31st. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.25. The company earned $4.46 billion during the quarter, compared to the consensus estimate of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive trailing twelve-month return on equity of 34.90%.

What ETFs hold Teva Pharmaceutical Industries' stock?

ETFs with the largest weight of Teva Pharmaceutical Industries (NYSE:TEVA) stock in their portfolio include iShares MSCI Israel ETF (EIS), VanEck Pharmaceutical ETF (PPH) and VanEck Israel ETF (ISRA).ARK Israel Innovative Technology ETF (IZRL).

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY24 earnings guidance on Wednesday, January, 31st. The company provided EPS guidance of $2.20-$2.50 for the period, compared to the consensus earnings per share estimate of $2.41. The company issued revenue guidance of $15.7-$16.3 billion, compared to the consensus revenue estimate of $15.57 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Lingotto Investment Management LLP (3.07%), Clal Insurance Enterprises Holdings Ltd (2.93%), Migdal Insurance & Financial Holdings Ltd. (2.58%), Harel Insurance Investments & Financial Services Ltd. (2.55%), Rubric Capital Management LP (1.63%) and AustralianSuper Pty Ltd (0.81%). Insiders that own company stock include Amir Weiss, David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric A Hughes, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard D Francis and Sven Dethlefs.
View institutional ownership trends
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:TEVA) was last updated on 3/1/2024 by MarketBeat.com Staff